在巴西评估阿尔茨海默病中药理疗法的成本效益
Price Udo Price1, Robert Heggie2, Julio Cesar Moriguti3
1School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, Brazil.
Value in health regional issues
|May 28, 2025
概括
标准护理的乙胆酶抑制剂在阿尔茨海默病 (AD) 管理中具有成本效益. 与20年来最好的支持性护理,lecanemab和donanemab相比,它们提供了最低的每年质量调整生命年 (QALY) 收益成本.
科学领域:
- 神经科学是一个神经科学.
- 药物经济学 药物经济学
- 老年病的医生 老年病的医生
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,是痴呆的主要原因,也是死亡和残疾的重要原因.
- 痴呆症带来了巨大的经济负担,预计到2050年巴西痴呆症护理成本将达到773亿美元.
- 评估药理干预措施的成本效益对于管理AD及其相关医疗保健成本至关重要.
研究的目的:
- 评估乙胆酶抑制剂 (标准护理 (SoC)) 在管理轻度阿尔茨海默病的成本效益.
- 为了比较SoC没有药理疗法 (最佳支持性护理[BSC]),lecanemab和donanemab.
- 从医疗保健和社会角度分析治疗成本和质量调整寿命 (QALYs) 在巴西的20年时间里.
主要方法:
- 开发了一个决策分析模型来模拟阿尔茨海默病的进展.
- 使用了巴西特定的成本和健康效益数据,并补充了文献数据.
- 成本和QALY每年折扣3.5%,成本转换为2024美元.
主要成果:
- 从医疗保健的角度来看,SoC的临床效果比BSC更大,每QALY的成本为5211美元.
- 对于lecanemab与SoC相比,每QALY获得的成本为2,098,225.25美元.
- 对于donanemab和lecanemab而言,每QALY获得的成本为1,460,400美元.
结论:
- 乙胆酶抑制剂 (SoC) 是对阿尔茨海默病的成本有效的药理干预措施.
- 与评估的替代方案相比,SoC在20年内提供了每QALY收益的最低成本.
- 这些发现支持继续使用SoC作为巴西轻度AD的首要治疗策略.
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Drug Therapy
107
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
107
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Psychosis: Goals of Pharmacotherapy
216
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
216


